A randomized double-blind trial of atomoxetine for cognitive impairments in 32 people with schizophrenia

Journal of Clinical Psychiatry

Volumn 70, Issue 4, 2009, Pages 518-525

  Kelly, Deanna L ^a,e   Buchanan, Robert W ^a   Boggs, Douglas L ^a   McMahon, Robert P ^a   Dickinson, Dwight ^b   Nelson, Matthew ^a,c   Gold, James M ^a   Ball, M Patricia ^a   Feldman, Stephanie ^a   Liu, Fang ^a   Conley, Robert R ^a,d  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b VA Capitol Health Care Network   (United States)

^c Sanofi Aventis

^d ELI LILLY AND COMPANY   (United States)

^e MARYLAND PSYCHIATRIC RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATOMOXETINE; BENZATROPINE; CHLORAL HYDRATE; LORAZEPAM; PLACEBO;

ABDOMINAL PAIN; ADULT; AGITATION; AKATHISIA; ANOREXIA; ANXIETY DISORDER; ARTICLE; ATTENTION; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITIVE DEFECT; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; INSOMNIA; MALAISE; MALE; NAUSEA; NEUROPSYCHOLOGICAL TEST; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESTLESSNESS; RIGIDITY; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SLEEP DISORDER; SORE THROAT; TREMOR; VERBAL MEMORY; VISUAL MEMORY; VOMITING; WEIGHT REDUCTION; WORKING MEMORY; XEROSTOMIA;

ADRENERGIC UPTAKE INHIBITORS; ANTIPSYCHOTIC AGENTS; BRIEF PSYCHIATRIC RATING SCALE; COGNITION DISORDERS; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PROPYLAMINES; SCHIZOPHRENIA; SEVERITY OF ILLNESS INDEX;

EID: 66349085040     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.08m04358     Document Type: Article

References (44)

1. Bowie CR, Harvey PD. Cognition in schizophrenia: impairments, determinants, and functional importance. Psychiatr Clin North Am 2005;28:613-633 (Pubitemid 41191137)
2. Gold JM. Cognitive deficits as treatment targets in schizophrenia. Schizophr Res 2004;72:21-28 (Pubitemid 39452902)
3. Matza LS, Buchanan R, Purdon S, et al. Measuring changes in functional status among patients with schizophrenia: the link with cognitive impairment. Schizophr Bull 2006;32(4):666-678 (Pubitemid 44412854)
4. Brekke JS, Hoe M, Long J, et al. How neurocognition and social cognition influence functional change during community-based psychosocial rehabilitation for individuals with schizophrenia. Schizophr Bull 2007;33(5):1247-1256 (Pubitemid 47347914)
5. Keefe RS, Bilder RM, Davis SM, et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry 2007;64(6):633-647 (Pubitemid 46878665)
6. Goldberg TE, Goldman RS, Burdick KE, et al. Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect? Arch Gen Psychiatry 2007;64:1115-1122
7. Bowie CR, Harvey PD. Treatment of cognitive deficits in schizophrenia. Curr Opin Investig Drugs 2006;7(7):608-613 (Pubitemid 44018342)
8. Marder SR. Drug initiatives to improve cognitive function. J Clin Psychiatry 2006;67(suppl 9):31-35; discussion 36-42 (Pubitemid 44369653)
9. Buchanan RW, Freedman R, Javitt DC, et al. Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia. Schizophr Bull 2007;33(5):1120-1130 (Pubitemid 47347922)
10. Tamminga CA. The neurobiology of cognition in schizophrenia. J Clin Psychiatry 2006;67(suppl 9):9-13; discussion 36-42 (Pubitemid 44369649)
11. Friedman JI, Stewart DG, Gorman JM. Potential noradrenergic targets for cognitive enhancement in schizophrenia. CNS Spectr 2004;9(5):350-355 (Pubitemid 38649723)
12. Corman SL, Fedutes BA, Culley CM. Atomoxetine: the first nonstimulant for the management of attention-deficit/hyperactivity disorder. Am J Health Syst Pharm 2004;61(22):2391-2399 (Pubitemid 40403582)
13. Tzavara ET, Bymaster FP, Overshiner CD, et al. Procholinergic and memory enhancing properties of the selective norepinephrine uptake inhibitor atomoxetine. Mol Psychiatry 2006;11(2):187-195 (Pubitemid 43164620)
14. Bymaster FP, Katner JS, Nelson DL, et al. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 2002;27(5):699-711 (Pubitemid 35335888)
15. Chamberlain SR, Del Campo N, Dowson J, et al. Atomoxetine improved response inhibition in adults with attention deficit/hyperactivity disorder. Biol Psychiatry 2007;62(9):977-984 (Pubitemid 47562368)
16. Faraone SV, Biederman J, Spencer T, et al. Atomoxetine and stroop task performance in adult attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2005;15(4):664-670 (Pubitemid 41434370)
17. Kelsey DK, Sumner CR, Casat CD, et al. Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial. Pediatrics 2004 Jul;114(1):e1-e8
18. Friedman JI, Carpenter D, Lu J, et al. A pilot study of adjunctive atomoxetine treatment to second-generation antipsychotics for cognitive impairment in schizophrenia. J Clin Psychopharmacol 2008;28(1):59-63
19. First MB, Spitzer RL, Gibbon M, et al. User's Guide for the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I), Clinician Version. New York, NY: Biometrics Research, New York State Psychiatric Institute; 1997
20. Randolph C, Tierney MC, Mohr E, et al. The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary clinical validity. J Clin Exp Neuropsychol 1998;20(3):310-319 (Pubitemid 28539551)
21. Wechsler D. Wechsler Adult Intelligence Scale. 3rd ed. San Antonio, Tex: The Psychological Corporation; 1997
22. Keefe RS, Goldberg TE, Harvey PD, et al. The Brief Assessment of Cognition in Schizophrenia: reliability, sensitivity, and comparison with a standard neurocognitive battery. Schizophr Res 2004;68(2-3):283-297 (Pubitemid 38526150)
23. Matthews CG, Klove H. Instruction Manual for the Adult Neuropsychology Test Battery. Madison, Wis: University of Wisconsin Medical School; 1964
24. Benton AL, Hamsher K. Multilingual Aphasia Examination. Iowa City, Iowa: AJA Associates, Inc; 1989
25. Woodcock RW, McGrew KS, Mather N. Woodcock-Johnson III Battery. Itasca, Ill: Riverside Publishing; 2001
26. Delis DC, Kramer JH, Kaplan E, et al. California Verbal Learning Test, 2nd ed. New York, NY: Psychological Corporation; 2000
27. Benedict RHB. Brief Visuospatial Memory Test-Revised. Odessa, Fla: Psychological Assessment Resources; 1997
28. Gordon M, Mettelman BB. Technical guide to the Gordon Diagnostic System. New York, NY: De Witt; 1987
29. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep 1962;10:799-812
30. Andreasen NC. The Scale for the Assessment of Negative Symptoms (SANS). Iowa City, Iowa: University of Iowa; 1983
31. Buchanan RW, Javitt DC, Marder SR, et al. The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments. Am J Psychiatry 2007;164(10):1593-1602 (Pubitemid 350069740)
32. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health; 1976:218-222
33. Buchanan RW, Breier A, Kirkpatrick B, et al. Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome. Am J Psychiatry 1998;155(6):751-760 (Pubitemid 28252653)
34. Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988 Sep;45(9):789-796 (Pubitemid 18222922)
35. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970;212:S11-S19
36. Guy W. ECDEU Assessment Manual for Psychopharmacology, Revised. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health; 1976: 534-537
37. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry 1989;154:672-676 (Pubitemid 19154942)
38. Pepe MS, Whitaker RC, Seidel K. Estimating and comparing univariate associations with application to the prediction of adult obesity. Stat Med 1999;18(2):163-173 (Pubitemid 29027697)
39. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B [Methodological] 1995;57(1):289-300
40. Conover WJ, Salsburg DS. Locally most powerful tests for detecting treatment effects when only a subset of patients can be expected to "respond" to treatment. Biometrics 1988;44(1):189-196
41. McMahon RP, Arndt S, Conley RR. More powerful two-sample tests for differences in repeated measures of adverse effects in psychiatric trials when only some patients may be at risk. Stat Med 2005;24(1):11-21 (Pubitemid 40074061)
42. Buchanan RW, Conley RR, Dickinson D, et al. Galantamine for the treatment of cognitive impairments in people with schizophrenia. Am J Psychiatry 2008;165(1):82-89
43. Freedman R, Olincy A, Buchanan RW, et al. Initial phase 2 trial of a nicotinic agonist in schizophrenia [published online ahead of print April 1, 2008]. Am J Psychiatry 2008;165(8):1040-1047. doi:10.1176/appi.ajp.2008.07071135
44. Buchanan RW, Davis M, Goff D, et al. A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia. Schizophr Bull 2005;31:5-19 (Pubitemid 41214353)